T cells contribute to tumor progression by favoring pro-tumoral properties of intra-tumoral myeloid cells in a mouse model for spontaneous melanoma

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Lengagne, Renée ^a,b,c   Pommier, Arnaud ^a,b,c   Caron, Jonathan ^a,b,c   Douguet, Laetitia ^a,b,c   Garcette, Marylène ^a,b,c   Kato, Masashi ^d   Avril, Marie Françoise ^a,b,c,e   Abastado, Jean Pierre ^f   Bercovici, Nadège ^a,b,c   Lucas, Bruno ^a,b,c   Prévost Blondel, Armelle ^a,b,c  

^a INSTITUT COCHIN   (France)

^b CNRS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d CHUBU UNIVERSITY   (Japan)

^e Service de Dermatologie ^*  (France)

^f AGENCY FOR SCIENCE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; INTERLEUKIN 2; CD11B ANTIGEN; DIFFERENTIATION ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; METALLOTHIONEIN; MONOCYTE MACROPHAGE DIFFERENTIATION ANTIGEN; MONOCYTE-MACROPHAGE DIFFERENTIATION ANTIGEN; PROTEIN RET; RET PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CANCER GROWTH; CARCINOGENESIS; CELL ACTIVITY; CELL INFILTRATION; CELL POLARITY; CELL POPULATION; CELL PROLIFERATION; CELL TYPE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ACTIVITY; ENZYME SYNTHESIS; LYMPHOCYTE PROLIFERATION; MELANOMA; MELANOMA CELL; METASTASIS POTENTIAL; MOUSE; NONHUMAN; ONCOGENE RET; SPLEEN CELL; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; WILD TYPE; ANIMAL; DISEASE COURSE; DISEASE MODEL; FEMALE; FLOW CYTOMETRY; GENETICS; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MOUSE MUTANT; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE;

MUS;

ANIMALS; ANTIGENS, CD11B; ANTIGENS, DIFFERENTIATION; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12; MALE; MELANOMA; METALLOTHIONEIN; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MYELOID CELLS; PROTO-ONCOGENE PROTEINS C-RET; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 79957523951     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020235     Document Type: Article

References (46)

1. Sica A, Bronte V, (2007) Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117: 1155-1166.
2. Serafini P, Borrello I, Bronte V, (2006) Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16: 53-65.
3. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, et al. (2008) Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111: 4233-4244.
4. Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, et al. (2010) Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 22: 238-244.
5. Youn JI, Gabrilovich DI, (2010) The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 40: 2969-2975.
6. Gabrilovich DI, Nagaraj S, (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162-174.
7. Li H, Han Y, Guo Q, Zhang M, Cao X, (2009) Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta1. J Immunol 182: 240-249.
8. Liu C, Yu S, Kappes J, Wang J, Grizzle WE, et al. (2007) Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood 109: 4336-4342.
9. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S, (2007) Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 179: 977-983.
10. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, et al. (2006) Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 116: 2777-2790.
11. Huang B, Pan PY, Li Q, Sato AI, Levy DE, et al. (2006) Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66: 1123-1131.
12. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI, (2008) Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 181: 5791-5802.
13. Whitworth PW, Pak CC, Esgro J, Kleinerman ES, Fidler IJ, (1990) Macrophages and cancer. Cancer Metastasis Rev 8: 319-351.
14. Biswas SK, Mantovani A, (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11: 889-896.
15. Gordon S, Taylor PR, (2005) Monocyte and macrophage heterogeneity. Nat Rev Immunol 5: 953-964.
16. Mantovani A, Allavena P, Sica A, (2004) Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer 40: 1660-1667.
17. Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, et al. (2006) A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 107: 2112-2122.
18. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A, (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555.
19. Saccani A, Schioppa T, Porta C, Biswas SK, Nebuloni M, et al. (2006) p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res 66: 11432-11440.
20. Sica A, Saccani A, Bottazzi B, Polentarutti N, Vecchi A, et al. (2000) Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J Immunol 164: 762-767.
21. Gazzaniga S, Bravo AI, Guglielmotti A, van Rooijen N, Maschi F, et al. (2007) Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Invest Dermatol 127: 2031-2041.
22. Miselis NR, Wu ZJ, Van Rooijen N, Kane AB, (2008) Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol Cancer Ther 7: 788-799.
23. Robinson-Smith TM, Isaacsohn I, Mercer CA, Zhou M, Van Rooijen N, et al. (2007) Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res 67: 5708-5716.
24. Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjallman AH, Ballmer-Hofer K, et al. (2006) Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer 95: 272-281.
25. Boonman ZF, Schurmans LR, van Rooijen N, Melief CJ, Toes RE, et al. (2006) Macrophages are vital in spontaneous intraocular tumor eradication. Invest Ophthalmol Vis Sci 47: 2959-2965.
26. Oosterling SJ, van der Bij GJ, Meijer GA, Tuk CW, van Garderen E, et al. (2005) Macrophages direct tumour histology and clinical outcome in a colon cancer model. J Pathol 207: 147-155.
27. Nardin A, Abastado JP, (2008) Macrophages and cancer. Front Biosci 13: 3494-3505.
28. de Visser KE, Korets LV, Coussens LM, (2005) De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7: 411-423.
29. Wong SC, Puaux AL, Chittezhath M, Shalova I, Kajiji TS, et al. (2010) Macrophage polarization to a unique phenotype driven by B cells. Eur J Immunol 40: 2296-2307.
30. Smyth MJ, Dunn GP, Schreiber RD, (2006) Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90: 1-50.
31. DeNardo DG, Andreu P, Coussens LM, (2010) Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev 29: 309-316.
32. Kato M, Takahashi M, Akhand AA, Liu W, Dai Y, et al. (1998) Transgenic mouse model for skin malignant melanoma. Oncogene 17: 1885-1888.
33. Eyles J, Puaux AL, Wang X, Toh B, Prakash C, et al. (2010) Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest 120: 2030-2039.
34. Lengagne R, Le Gal FA, Garcette M, Fiette L, Ave P, et al. (2004) Spontaneous vitiligo in an animal model for human melanoma: role of tumor-specific CD8+ T cells. Cancer Res 64: 1496-1501.
35. Malissen M, Gillet A, Ardouin L, Bouvier G, Trucy J, et al. (1995) Altered T cell development in mice with a targeted mutation of the CD3-epsilon gene. Embo J 14: 4641-4653.
36. Soudja SM, Wehbe M, Mas A, Chasson L, de Tenbossche CP, et al. (2010) Tumor-initiated inflammation overrides protective adaptive immunity in an induced melanoma model in mice. Cancer Res 70: 3515-3525.
37. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, et al. (2008) Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells. J Immunol 181: 4666-4675.
38. Gordon S, (2003) Alternative activation of macrophages. Nat Rev Immunol 3: 23-35.
39. Biswas SK, Sica A, Lewis CE, (2008) Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol 180: 2011-2017.
40. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, et al. (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25: 677-686.
41. Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, et al. (2009) The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest 119: 3011-3023.
42. Daniel D, Meyer-Morse N, Bergsland EK, Dehne K, Coussens LM, et al. (2003) Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med 197: 1017-1028.
43. Ibe S, Qin Z, Schuler T, Preiss S, Blankenstein T, (2001) Tumor rejection by disturbing tumor stroma cell interactions. J Exp Med 194: 1549-1559.
44. DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, et al. (2009) CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16: 91-102.
45. Lengagne R, Graff-Dubois S, Garcette M, Renia L, Kato M, et al. (2008) Distinct role for CD8 T cells toward cutaneous tumors and visceral metastases. J Immunol 180: 130-137.
46. Trinchieri G, (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3: 133-146.